Atlas Trials

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Clinical trial NCT00694850 · COMPLETED

Trial details

NCT number
NCT00694850
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hypertension, Pulmonary
Start date
2008-08-02
Primary completion
2025-07-03
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.